

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/023,888	12/21/2001	William Canfield	203515US77	5416
22850	7590 07/08/200		EXAMINER	
OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT, P.C.			SLOBODYANSKY, ELIZABETH	
1940 DUKE ALEXANDE	STREET RIA, VA 22314		ART UNIT	PAPER NUMBER
TILLM INDI	, , 22011		1652	

DATE MAILED: 07/08/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

,	Application No.	Applicant(s)	
Advisory Action	10/023,888	CANFIELD ET AL.	
Advisory Action	Examiner	Art Unit	7
	Elizabeth Slobodyansky, PhD	1652	
The MAILING DATE of this communication appe	ars on the cover sheet with the o	correspondence address	7
	PLICATION IN CONDITION FO void abandonment of this applied a timely filed amendment whi	R ALLOWANCE. cation. A proper reply to a ch places the application in	
PERIOD FOR RE	PLY [check either a) or b)]		
a) The period for reply expiresmonths from the mailing of the period for reply expires on: (1) the mailing date of this Adverse, will the statutory period for reply expire later the ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS 706.07(f).  Extensions of time may be obtained under 37 CFR 1.136(a). The dath have been filed is the date for purposes of determining the period of extensions of the status of the shortened (b) above, if checked. Any reply received by the Office later than three moterned patent term adjustment. See 37 CFR 1.704(b).	isory Action, or (2) the date set forth in the an SIX MONTHS from the mailing date of FILED WITHIN TWO MONTHS OF THe te on which the petition under 37 CFR 1. sion and the corresponding amount of the statutory period for reply originally set in	f the final rejection. E FINAL REJECTION. See MPEP 136(a) and the appropriate extension fee efee. The appropriate extension fee under the final Office action; or (2) as set forth in	
<ul> <li>1. ☐ A Notice of Appeal was filed on <u>08 June 2004</u>. App 37 CFR 1.192(a), or any extension thereof (37 CF</li> <li>2. ☐ The proposed amendment(s) will not be entered b</li> </ul>	R 1.191(d)), to avoid dismissal		
		(see NOTE below):	
(a) they raise new issues that would require furth		see NOTE below),	ŀ
(b) they raise the issue of new matter (see Note to		carially raduaing as simplifying the	
(c) they are not deemed to place the application issues for appeal; and/or	in better form for appear by mai	enally reducing or simplifying the	
(d) they present additional claims without cancel NOTE:	ing a corresponding number of	finally rejected claims.	
3. Applicant's reply has overcome the following rejection.	ction(s):		
4. Newly proposed or amended claim(s) would canceling the non-allowable claim(s).	• /	separate, timely filed amendment	
5. ☐ The a) ☐ affidavit, b) ☐ exhibit, or c) ☐ request fo application in condition for allowance because:		sidered but does NOT place the	
6. The affidavit or exhibit will NOT be considered be raised by the Examiner in the final rejection.	cause it is not directed SOLELY	to issues which were newly	
7. For purposes of Appeal, the proposed amendment explanation of how the new or amended claims w			
The status of the claim(s) is (or will be) as follows:			
Claim(s) allowed: 22,56 and 74.			
Claim(s) objected to:			
Claim(s) rejected: <u>26, 28-37 and 70-73</u> .			
Claim(s) withdrawn from consideration: <u>54,55 and</u>		the Francisco	
8. The drawing correction filed on is a) app			
9. Note the attached Information Disclosure Stateme	nt(s)( PTO-1449) Paper No(s).	·	
10. ☐ Other:		Elizabeth Slobodyarsky, PhD Primary Examiner Art Unit: 1652	No.

Application No.

## Continuation Sheet (PTOL-303)

Claim 26 would be allowable if amended to recite a wash step at 65 C. Claim 70 recites enzymes that are not hydrolases. Claim 35 recites "Genenase". There is no enzyme with said name according to the Enzyme Nomenclature. Claim 75 is drawn to a method of use the polypeptide of SEQ ID NO:22 while reciting the method of making of a different compound.